イフィナタマブderuxtecanベースの治療の組み合わせの臨床研究または転移性去勢抵抗性前立腺癌(MCRPC)を治療するための単剤療法として(MK-2400-01A/IDEATE-PROSTATE02)
MK-2400-01A Sududy:フェーズ1/2、MK-2400-U01マスタープロトコルのオープンラベル傘下補理解法は、転移性カクリー化 - レジスタンレストレス酸塩能力普通の参加者において、イフィナタマブデルクテカンベースの治療の組み合わせまたはイフィナタマブデュアクテカン単独でのみの安全性と有効性を評価します(MCRPC2)
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about:
- The safety of the study treatment and if people tolerate it.
- A safe dose level of I-DXd that can be used with other treatments.
- Participant levels of prostate specific antigen (PSA) during treatment.
調査の概要
状態
条件
詳細な説明
This sub study MK-2400-01A assesses treatments for metastatic castration-resistant prostate cancer (mCRPC).
The master screening protocol is MK-2400-U01
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Toll Free Number
- 電話番号:1-888-577-8839
- メール:Trialsites@msd.com
研究場所
-
-
-
Dublin、アイルランド、D09 V2N0
- 募集
- Beaumont Hospital, Dublin ( Site 0465)
-
コンタクト:
- Study Coordinator
- 電話番号:0035318092010
-
Dublin、アイルランド、D24 NR0A
- 募集
- Tallaght University Hospital ( Site 0462)
-
コンタクト:
- Study Coordinator
- 電話番号:0035314144209
-
-
Dublin
-
Dublin、Dublin、アイルランド、D04 T6F4
- 募集
- St Vincent's University Hospital ( Site 0463)
-
コンタクト:
- Study Coordinator
- 電話番号:+353 1 221 4982
-
-
-
-
California
-
Los Angeles、California、アメリカ、90095
- 募集
- UCLA Hematology & Oncology ( Site 0003)
-
コンタクト:
- Study Coordinator
- 電話番号:310-829-5471
-
Orange、California、アメリカ、92868
- 募集
- University of California-Irvine Medical Center ( Site 0016)
-
コンタクト:
- Study Coordinator
- 電話番号:714-456-5153
-
San Francisco、California、アメリカ、94158
- 募集
- UCSF Medical Center at Mission Bay ( Site 0034)
-
コンタクト:
- Study Coordinator
- 電話番号:415-502-2097
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- 募集
- MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)
-
コンタクト:
- Study Coordinator
- 電話番号:202-877-3061
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- 募集
- University of Michigan ( Site 0021)
-
コンタクト:
- Study Coordinator
- 電話番号:734-936-4000
-
-
New York
-
New York、New York、アメリカ、10065
- 募集
- Memorial Sloan Kettering Cancer Center ( Site 0006)
-
コンタクト:
- Study Coordinator
- 電話番号:347-798-8620
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15232
- 募集
- UPMC Hillman Cancer Center ( Site 0014)
-
コンタクト:
- Study Coordinator
- 電話番号:412-647-2811
-
-
Tennessee
-
Germantown、Tennessee、アメリカ、38138
- 募集
- The West Clinic, PLLC dba West Cancer Center ( Site 0005)
-
コンタクト:
- Study Coordinator
- 電話番号:901-683-0055
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- 募集
- Fred Hutchinson Cancer Center ( Site 0013)
-
コンタクト:
- Study Coordinator
- 電話番号:206-288-1111
-
-
-
-
-
La Rioja、アルゼンチン、F5300COE
- 募集
- Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0200)
-
コンタクト:
- Study Coordinator
- 電話番号:54-380-443-6443
-
-
Buenos Aires
-
Ciudad Autónoma de Buenos Aires、Buenos Aires、アルゼンチン、C1426ANZ
- 募集
- Instituto Alexander Fleming ( Site 0202)
-
コンタクト:
- Study Coordinator
- 電話番号:5411 3221 8900
-
-
-
-
Cambridgeshire
-
Cambridge、Cambridgeshire、イギリス、CB2 2QQ
- 募集
- Addenbrooke's Hospital ( Site 0747)
-
コンタクト:
- Study Coordinator
- 電話番号:00441223216083
-
-
London, City of
-
London、London, City of、イギリス、NW3 2QG
- 募集
- Royal Free Hospital ( Site 0743)
-
コンタクト:
- Study Coordinator
- 電話番号:00442077940500/2237
-
London、London, City of、イギリス、EC1A 7BE
- 募集
- St Bartholomew's Hospital ( Site 0749)
-
コンタクト:
- Study Coordinator
- 電話番号:00442073777000
-
-
Surrey
-
London、Surrey、イギリス、SM3 5PT
- 募集
- Royal Marsden Hospital (Sutton) ( Site 0741)
-
コンタクト:
- Study Coordinator
- 電話番号:0203 437 3500
-
-
-
-
-
Haifa、イスラエル、3109601
- 募集
- Rambam Health Care Campus ( Site 0400)
-
コンタクト:
- Study Coordinator
- 電話番号:972(47776234)
-
Jerusalem、イスラエル、9112001
- 募集
- Hadassah Medical Center ( Site 0404)
-
コンタクト:
- Study Coordinator
- 電話番号:+97226777333
-
Petah Tikva、イスラエル、4941492
- 募集
- Rabin Medical Center ( Site 0402)
-
コンタクト:
- Study Coordinator
- 電話番号:+972544594048
-
Ramat Gan、イスラエル、5265601
- 募集
- Sheba Medical Center ( Site 0401)
-
コンタクト:
- Study Coordinator
- 電話番号:+97235303030
-
Tel Aviv、イスラエル、6423906
- 募集
- Sourasky Medical Center ( Site 0403)
-
コンタクト:
- Study Coordinator
- 電話番号:+97236947832
-
-
-
-
-
Brescia、イタリア、25123
- 積極的、募集していない
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 0432)
-
Milan、イタリア、20133
- 募集
- Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0431)
-
コンタクト:
- Study Coordinator
- 電話番号:+390223904449
-
Naples、イタリア、80131
- 募集
- A.O.U. Federico II di Napoli ( Site 0435)
-
コンタクト:
- Study Coordinator
- 電話番号:+390817463660
-
Roma、イタリア、00168
- 募集
- Fondazione Policlinico Universitario Agostino Gemelli ( Site 0433)
-
コンタクト:
- Study Coordinator
- 電話番号:+390630155202
-
-
Torino
-
Orbassano、Torino、イタリア、10143
- 募集
- AOU San Luigi Gonzaga di Orbassano ( Site 0434)
-
コンタクト:
- Study Coordinator
- 電話番号:00390119026534
-
-
-
-
Gelderland
-
Ede、Gelderland、オランダ、6716 RP
- 募集
- Ziekenhuis Gelderse Vallei ( Site 0683)
-
コンタクト:
- Study Coordinator
- 電話番号:+31 318 435499
-
Nijmegen、Gelderland、オランダ、6525 GA
- 募集
- UMC St. Radboud ( Site 0679)
-
コンタクト:
- Study Coordinator
- 電話番号:+31 24 361 1111
-
-
Provincie Friesland
-
Drachten、Provincie Friesland、オランダ、9202 NN
- 募集
- Nij Smellinghe ( Site 0684)
-
コンタクト:
- Study Coordinator
- 電話番号:0512 588 888
-
-
-
-
New South Wales
-
Macquarie University、New South Wales、オーストラリア、2109
- 募集
- Macquarie University-MQ Health Clinical Trials Unit ( Site 0801)
-
コンタクト:
- Study Coordinator
- 電話番号:+61 2 9812 2956
-
-
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 4E6
- 募集
- BC Cancer - Vancouver Center ( Site 0103)
-
コンタクト:
- Study Coordinator
- 電話番号:6048776000
-
-
Ontario
-
Toronto、Ontario、カナダ、M4N 3M5
- 募集
- Sunnybrook Research Institute ( Site 0109)
-
コンタクト:
- Study Coordinator
- 電話番号:4164806100
-
Toronto、Ontario、カナダ、M5G 2M9
- 募集
- Princess Margaret Cancer Centre ( Site 0102)
-
コンタクト:
- Study Coordinator
- 電話番号:4169464501
-
-
Quebec
-
Montreal、Quebec、カナダ、H3T 1E2
- 募集
- Jewish General Hospital ( Site 0108)
-
コンタクト:
- Study Coordinator
- 電話番号:5143408110
-
Sherbrooke、Quebec、カナダ、J1H 5N4
- 募集
- CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0107)
-
コンタクト:
- Study Coordinator
- 電話番号:8197802222
-
-
-
-
-
Madrid、スペイン、28034
- 募集
- Hospital Universitario Ramon y Cajal ( Site 0620)
-
コンタクト:
- Study Coordinator
- 電話番号:+34913368263
-
Madrid、スペイン、28041
- 募集
- Hospital Universitario 12 de Octubre ( Site 0622)
-
コンタクト:
- Study Coordinator
- 電話番号:+34608464547
-
Madrid、スペイン、28040
- 募集
- Hospital Clinico San Carlos ( Site 0618)
-
コンタクト:
- Study Coordinator
- 電話番号:+34913303546
-
Seville、スペイン、41013
- 募集
- Hospital Universitario Virgen del Rocio ( Site 0619)
-
コンタクト:
- Study Coordinator
- 電話番号:+34955013068
-
-
Barcelona
-
L Hospitalet Del Llobregat、Barcelona、スペイン、08908
- 募集
- ICO L Hospitalet ( Site 0617)
-
コンタクト:
- Study Coordinator
- 電話番号:+34932607744
-
-
-
-
Maule Region
-
Talca、Maule Region、チリ、3465584
- 募集
- Clinica Universidad Catolica del Maule ( Site 0236)
-
コンタクト:
- Study Coordinator
- 電話番号:56992992913
-
-
Region M. de Santiago
-
Santiago、Region M. de Santiago、チリ、8420383
- 募集
- Bradfordhill ( Site 0231)
-
コンタクト:
- Study Coordinator
- 電話番号:+56229490970
-
Santiago、Region M. de Santiago、チリ、7560908
- 募集
- Centro de Oncología de Precisión ( Site 0241)
-
コンタクト:
- Study Coordinator
- 電話番号:+56225189885
-
Santiago、Region M. de Santiago、チリ、7500921
- 募集
- Fundación Arturo López Pérez ( Site 0232)
-
コンタクト:
- Study Coordinator
- 電話番号:56224205098
-
-
Valparaiso
-
Viña del Mar、Valparaiso、チリ、2520598
- 募集
- ONCOCENTRO APYS ( Site 0234)
-
コンタクト:
- Study Coordinator
- 電話番号:+56323320850
-
-
-
-
-
Adana、トルコ(Türkiye)、01250
- 募集
- Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0650)
-
コンタクト:
- Study Coordinator
- 電話番号:+903223271274
-
Ankara、トルコ(Türkiye)、06230
- 募集
- Hacettepe Universitesi Tip Fakultesi ( Site 0648)
-
コンタクト:
- Study Coordinator
- 電話番号:+90 312 305 50 00
-
Ankara、トルコ(Türkiye)、06800
- 募集
- Ankara Bilkent Şehir Hastanesi ( Site 0654)
-
コンタクト:
- Study Coordinator
- 電話番号:+903125526000
-
Ankara、トルコ(Türkiye)、06620
- 募集
- Ankara Universitesi Tip Fakultesi Hastanesi ( Site 0653)
-
コンタクト:
- Study Coordinator
- 電話番号:+903122126040
-
Istanbul、トルコ(Türkiye)、34010
- 募集
- Koç Üniversitesi Hastanesi ( Site 0656)
-
コンタクト:
- Study Coordinator
- 電話番号:+905369410661
-
Istanbul、トルコ(Türkiye)、34098
- 募集
- Istanbul Universitesi Cerrahpasa ( Site 0649)
-
コンタクト:
- Study Coordinator
- 電話番号:+902124143000
-
Rize、トルコ(Türkiye)、53020
- 募集
- Recep Tayyip Erdogan University Training and Research Hospital ( Site 0655)
-
コンタクト:
- Study Coordinator
- 電話番号:+904642130491
-
-
-
-
-
Hamburg、ドイツ、20246
- 募集
- Universitaetsklinikum Hamburg-Eppendorf ( Site 0524)
-
コンタクト:
- Study Coordinator
- 電話番号:+4915222815585
-
-
Baden-Wurttemberg
-
Heidelberg、Baden-Wurttemberg、ドイツ、69120
- 募集
- NCT ( Site 0528)
-
コンタクト:
- Study Coordinator
- 電話番号:00496221566857
-
Ulm、Baden-Wurttemberg、ドイツ、89081
- 募集
- Universitaetsklinikum Ulm. ( Site 0530)
-
コンタクト:
- Study Coordinator
- 電話番号:+4973150058188
-
-
Thuringia
-
Jena、Thuringia、ドイツ、07747
- 募集
- Universitaetsklinikum Jena ( Site 0525)
-
コンタクト:
- Study Coordinator
- 電話番号:+49-3641-9-329901
-
-
-
-
-
Auckland、ニュージーランド、1023
- 募集
- Auckland City Hospital ( Site 0831)
-
コンタクト:
- Study Coordinator
- 電話番号:+6493074949
-
-
-
-
Gironde
-
Bordeaux、Gironde、フランス、33000
- 募集
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 0498)
-
コンタクト:
- Study Coordinator
- 電話番号:+33556333261
-
-
Nord
-
Lille、Nord、フランス、59000
- 募集
- Centre Oscar Lambret ( Site 0495)
-
コンタクト:
- Study Coordinator
- 電話番号:+333 20 29 56 06
-
-
Pays de la Loire Region
-
Saint-Herblain、Pays de la Loire Region、フランス、44800
- 募集
- Institut De Cancerologie De L Ouest ( Site 0494)
-
コンタクト:
- Study Coordinator
- 電話番号:+33240679900
-
-
Pyrenees-Atlantiques
-
Bayonne、Pyrenees-Atlantiques、フランス、64100
- 募集
- Centre Hospitalier de la Cote Basque ( Site 0496)
-
コンタクト:
- Study Coordinator
- 電話番号:+33559443762
-
-
Rhone
-
Pierre-Bénite、Rhone、フランス、69310
- 募集
- centre hospitalier lyon sud ( Site 0497)
-
コンタクト:
- Study Coordinator
- 電話番号:33 4 78 86 43 24
-
-
-
-
-
São Paulo、ブラジル、01221-020
- 募集
- IPITEC ( Site 0275)
-
コンタクト:
- Study Coordinator
- 電話番号:+551194322-6006
-
São Paulo、ブラジル、03102-006
- 募集
- IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0269)
-
コンタクト:
- Study Coordinator
- 電話番号:+551144500360
-
-
Rio Grande do Norte
-
Natal、Rio Grande do Norte、ブラジル、59062-000
- 募集
- Liga Norte Riograndense Contra o Câncer ( Site 0271)
-
コンタクト:
- Study Coordinator
- 電話番号:(84) 4009-5595
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、ブラジル、90035-001
- 募集
- Hospital Moinhos de Vento ( Site 0278)
-
コンタクト:
- Study Coordinator
- 電話番号:+55 51 3314-3209
-
Porto Alegre、Rio Grande do Sul、ブラジル、90020-090
- 募集
- Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0270)
-
コンタクト:
- Study Coordinator
- 電話番号:+555132148151
-
-
São Paulo
-
Bragança Paulista、São Paulo、ブラジル、12916-542
- 募集
- Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0268)
-
コンタクト:
- Study Coordinator
- 電話番号:+551124901366
-
Ribeirão Preto、São Paulo、ブラジル、14048900
- 募集
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) ( Site 0273)
-
コンタクト:
- Study Coordinator
- 電話番号:(16) 3963-6487
-
São José do Rio Preto、São Paulo、ブラジル、15090-000
- 募集
- Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0263)
-
コンタクト:
- Study Coordinator
- 電話番号:+55 17 99625-3919
-
São Paulo、São Paulo、ブラジル、01327-001
- 募集
- Hospital Alemao Oswaldo Cruz ( Site 0279)
-
コンタクト:
- Study Coordinator
- 電話番号:55 11 3549-0009
-
-
-
-
Greater Poland Voivodeship
-
Poznan、Greater Poland Voivodeship、ポーランド、60-355
- 募集
- Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 0590)
-
コンタクト:
- Study Coordinator
- 電話番号:+61 854 79 87
-
-
Masovian Voivodeship
-
Warsaw、Masovian Voivodeship、ポーランド、02-781
- 募集
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0586)
-
コンタクト:
- Study Coordinator
- 電話番号:+48 22 546 33 81
-
-
Pomeranian Voivodeship
-
Gdansk、Pomeranian Voivodeship、ポーランド、80-214
- 募集
- Uniwersyteckie Centrum Kliniczne ( Site 0588)
-
コンタクト:
- Study Coordinator
- 電話番号:+48 58 584 44 66
-
-
West Pomeranian Voivodeship
-
Koszalin、West Pomeranian Voivodeship、ポーランド、75-581
- 募集
- Szpital Wojewódzki im. M.Kopernika Oddział Onk. Klinicznej z Pododdziałem Chemioterapii Jednodniowej ( Site 0587)
-
コンタクト:
- Study Coordinator
- 電話番号:+48943488930
-
-
-
-
-
Taichung、台湾、40705
- 募集
- Taichung Veterans General Hospital ( Site 0902)
-
コンタクト:
- Study Coordinator
- 電話番号:+886423592525
-
Taipei、台湾、11217
- 募集
- Taipei Veterans General Hospital ( Site 0901)
-
コンタクト:
- Study Coordinator
- 電話番号:+886228712121
-
-
-
-
-
Seoul、韓国、06351
- 募集
- Samsung Medical Center ( Site 0926)
-
コンタクト:
- Study Coordinator
- 電話番号:+82234103459
-
Seoul、韓国、03722
- 積極的、募集していない
- Severance Hospital Yonsei University Health System ( Site 0924)
-
-
Seoul
-
Songpagu、Seoul、韓国、05505
- 募集
- Asan Medical Center ( Site 0925)
-
コンタクト:
- Study Coordinator
- 電話番号:+82230105977
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
- Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before Screening
- Has current evidence of distant metastatic disease
- Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after treatment
- Participants receiving bone resorptive therapy (including, but not limited to bisphosphonate or denosumab) must have been on stable doses for ≥4 weeks before allocation/randomization
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 10 days before allocation/randomization
- Has prior treatment with poly-ADP-ribose polymerase inhibitors (PARPi) if indicated by local approved regimen or were deemed ineligible to receive PARPi by the investigator
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use (except for a history of radiation pneumonitis that did not require steroids), current ILD, clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out
- Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
- Uncontrolled or significant cardiovascular disease
- History of pituitary dysfunction
- Poorly controlled diabetes mellitus
- History or current condition of adrenal insufficiency (eg, Addison's disease)
- Has received prior treatment with taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC).
- Chronic steroid treatment (dose of >10 mg daily prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease), topical steroids (for mild skin conditions), or intra-articular steroid injections
- Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active autoimmune disease that has required systemic treatment in the past 2 years
- History of allogeneic tissue/solid organ transplant
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Docetaxel
Participants will receive docetaxel at a determined dose every 3 weeks (Q3W) for a maximum of 10 cycles. Each cycle is 21 days. |
Administered via Intravenous (IV) infusion at a specified dose on specified days |
|
実験的:Ifinatamab Deruxtecan (I-DXd)
Participants will receive I-DXd at a determined dose Q3W until unacceptable toxicity, progressive disease (PD), death or withdrawal of consent. |
Administered via IV infusion at a specified dose on specified days
他の名前:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. |
|
実験的:I-DXd + Opevesostat
Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS opevesostat at a determined dose until any of the criterion for discontinuation of study intervention is met. |
Administered via IV infusion at a specified dose on specified days
他の名前:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. Administered orally at a specified dose on specified days
他の名前:
|
|
実験的:I-DXd +ARPI (Abiraterone or Enzalutamide)
Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS ARPI (Androgen Receptor Pathway Inhibitor) - Abiraterone acetate OR Enzalutamide at a determined dose until any of the criterion for discontinuation of study intervention is met. |
Administered via IV infusion at a specified dose on specified days
他の名前:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. Administered orally at a specified dose on specified days Administered orally at a specified dose on specified days |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Efficacy Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
時間枠:Up to approximately 21 days
|
The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for >1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing >25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity. |
Up to approximately 21 days
|
|
Efficacy Phase: Number of Participants Who Experienced an Adverse Event (AE)
時間枠:Up to approximately 54 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 54 months
|
|
Efficacy Phase: Number of Participants Who Discontinued Study Intervention Due to an AE
時間枠:Up to approximately 24 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 24 months
|
|
Efficacy Phase: Prostate-Specific Antigen (PSA) response rate
時間枠:Up to approximately 54 months
|
PSA response is defined per prostate cancer working group (PCWG) criteria as a reduction in the PSA level of 50% or more from baseline measured at consecutive assessments at least 3 weeks apart. |
Up to approximately 54 months
|
|
Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
時間枠:Up to approximately 21 days
|
The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for >1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing >25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity. |
Up to approximately 21 days
|
|
Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE) - Combination Arms Only
時間枠:Up to approximately 21 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 21 days
|
|
Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AE - Combination Arms Only
時間枠:Up to approximately 21 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 21 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate (ORR)
時間枠:Up to approximately 54 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per PCWG3-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 54 months
|
|
Radiographic Progression-Free Survival (rPFS)
時間枠:Up to approximately 54 months
|
rPFS is defined as the time from randomization to the first documented progressive disease (PD) per PCWG3-modified RECIST 1.1 based on BICR or death due to any cause, whichever occurred first. Per PCWG3-modified RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions or ≥2 new bone lesions was also considered PD. PCWG3-modified RECIST is similar to RECIST 1.1 with the exception that a confirmation assessment of PD (>4 weeks after the initial PD) is required for participants who remain on treatment following a documented PD per RECIST 1.1 and PCWG3 rules include new bone lesions. The rPFS per PCWG3-modified RECIST as assessed by BICR for all participants is presented. The nonparametric Kaplan-Meier method will be used to estimate the rPFS curve in each treatment arm |
Up to approximately 54 months
|
|
Overall Survival (OS)
時間枠:Up to approximately 54 months
|
Overall survival (OS) is defined as the time from randomization to death due to any cause. The nonparametric Kaplan-Meier method will be used to estimate the survival curves. |
Up to approximately 54 months
|
|
Duration of Response (DOR)
時間枠:Up to approximately 54 months
|
DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per PCWG3-modified RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of ≥ 2 new bone lesions is also considered PD. DOR as assessed by BICR is presented. The nonparametric Kaplan-Meier method will be used to estimate the DOR in each treatment arm. |
Up to approximately 54 months
|
|
Time from allocation/randomization to initiation of the first subsequent anticancer therapy (TFST)
時間枠:Up to approximately 54 months
|
TFST is defined as the time from randomization to initiation of the first subsequent anticancer therapy or death, whichever occurs first. The nonparametric Kaplan-Meier method will be used to estimate the TFST in each treatment arm. |
Up to approximately 54 months
|
|
Time to Prostate-Specific Antigen (PSA) Progression
時間枠:Up to approximately 54 months
|
Time to PSA progression is defined as the time from randomization to PSA progression. Participants without PSA progression will be censored at the last PSA assessment date. The PSA progression date is defined as the date of: 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, OR 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. |
Up to approximately 54 months
|
|
Time to pain progression (TTPP)
時間枠:Up to approximately 54 months
|
The time from allocation/randomization to pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 "worst pain in 24 hours" and by the Analgesic Quantification Algorithm (AQA) score. |
Up to approximately 54 months
|
協力者と研究者
スポンサー
協力者
捜査官
- スタディディレクター:Medical Director、Merck Sharp & Dohme LLC
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2400-01A
- MK-2400-01A (その他の識別子:MSD)
- U1111-1310-5406 (レジストリ識別子:UTN)
- IDeate-Prostate02 (その他の識別子:MSD)
- 2024-516036-94-00 (レジストリ識別子:EU CT)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。